article thumbnail

STAT+: Juul spent big to court Black leaders to promote its e-cigarettes, new documents show

STAT

Documents released this week shed new light on an aggressive strategy from vape maker Juul to court Black leaders, including the Rev. Al Sharpton, to publicly support its e-cigarettes. It’s not clear how much the company ultimately spent on the partnerships. Continue to STAT+ to read the full story…

article thumbnail

STAT+: HCA to expand the use of AI tool to automate clinical documentation in ER

STAT

HCA Healthcare, the largest for-profit hospital chain in the United States, is planning to expand the use of an artificial intelligence tool to document doctor-patient interactions in its emergency rooms.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

STAT+: MD Anderson tried — and failed — to resolve research credit dispute between two scientists, new documents show

STAT

High-ranking officials at the cancer center tried — and failed — to resolve the feud, and documents obtained by STAT shed new light on the deep divisions at the heart of this case. These documents are alluded to in legal filings but have not been previously reported.

article thumbnail

STAT+: Microsoft to embed AI tool for clinical documentation in Epic’s health records software

STAT

Microsoft on Thursday said it will launch its artificial intelligence tool for automating clinical documentation within health records software made by Epic, a move to embed the technology in health systems nationwide.

article thumbnail

The food industry has tried to stack a key nutrition policy panel with its preferred experts, documents show

STAT

WASHINGTON — There’s a panel of 20 nutrition experts that has outsized influence on the American diet — and the food industry has worked hard to get friendly researchers into the group, new documents obtained by STAT show.

article thumbnail

STAT+: FDA reviewers had string of concerns about Sarepta’s gene therapy for Duchenne, documents show

STAT

Reviewers at the Food and Drug Administration concluded that Sarepta Therapeutics did not show that its gene therapy for Duchenne muscular dystrophy will likely benefit patients and left key safety concerns, according to briefing documents released Wednesday.

article thumbnail

Episode 908: Finally, All the VTE Recommendations In One Document!

Pharmacy Joe

Episode 908: Finally, All the VTE Recommendations In One Document! This meant that any unchanged guidance statements from the 2012 9th edition were still considered to be part of the guidelines, but were not reprinted in the 2016 document. appeared first on Pharmacy Joe.